Skip to main content


The use of MDMA-assisted psychotherapy for the treatment of PTSD could receive final approval by the FDA by 2022, Rick Doblin, PhD, of the Multidisciplinary Association for Psychedelic Studies told Psych Congress 2020 preconference attendees.
A session being presented at Psych Congress 2020 will educate attendees on the practice of combining ketamine treatment with psychotherapy for patients with treatment-resistant depression (TRD).
Psych Congress cochair Charles Raison, MD, a leading researcher in the field of immune-brain interactions, explains how increased inflammation may affect response to psychotherapy.
As psychotherapy continues to evolve, the challenge now is to rebrand and reposition the powerful healthcare resource it has become.
Our field can hardly rescue primary care, but we can help it regain its proud tradition by reinforcing the importance of a comprehensive focus on health and illness.
Back to Top